Intended for healthcare professionals


Risk-benefit ratio must be taken into account

BMJ 1996; 313 doi: (Published 14 December 1996) Cite this as: BMJ 1996;313:1553
  1. Stuart Dollow
  1. Senior medical adviser Medical Department, Roche Products, PO Box 8, Welwyn Garden City AL7 3AY

    EDITOR,—P J Barrett and colleagues report that mefloquine is associated with an excess of neuropsychiatric adverse events compared with chloroquine plus proguanil (27.4% v 16.0%).1 While there are similarities in methodology between the authors' study and Steffen et al's larger study,2 there are crucial differences in assessment criteria. I propose that any differences in incidence reports are a function of the defining criteria and that this may account for the disparities in perceptions of the tolerability of mefloquine. Nevertheless, I wish to make …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription